Schering receives EU approval for MRA contrast agent
The European Union has cleared Schering AG's contrast agent Gadovist 1.0 for use in magnetic resonance angiography (MRA).
Gadovist 1.0 has been marketed since 1999 in Europe for MR imaging of the brain and spine.
MRA is designed as a minimally invasive technology for the detection of vascular disease. It includes stenotic or occlusive changes of the arteries leading to infarction, thrombosis and embolism. Gadovist 1.0 can be used for diagnosis, therapy planning and follow-up of vascular disease.
Gadovist 1.0 has been marketed since 1999 in Europe for MR imaging of the brain and spine.
MRA is designed as a minimally invasive technology for the detection of vascular disease. It includes stenotic or occlusive changes of the arteries leading to infarction, thrombosis and embolism. Gadovist 1.0 can be used for diagnosis, therapy planning and follow-up of vascular disease.